Antisense ATL1102 final phase 2 DMD results meet primary endpoint and exceed expectations on secondary endpoints

This article was originally published here

Importantly, the final trial results have also confirmed the drug’s positive effects on the secondary trial endpoints that assessed the drug’s activity and efficacy including measuring the effects

The post Antisense ATL1102 final phase 2 DMD results meet primary endpoint and exceed expectations on secondary endpoints appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply